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Abstract- Metabolic syndrome is a cluster of conditions which enhance the risk of metabolic and 
cardiovascular diseases such as diabetes mellitus, dyslipidemia, or hypertension. Obesity plays a pivotal role 
in the pathogenesis of metabolic syndrome. French maritime Pine bark extract (PBE) in addition to its 
antioxidant properties, has protective effects on metabolic syndrome component through several mechanisms. 
At present, there are few data on the net impact of PBE on metabolic syndrome factors in obesity. This trial 
report the results of 2-month period supplementation of 38 obese women received weight loss diet and PBE 
(150mg/day) or placebo. The metabolic syndrome parameters and body composition were assessed at the 
beginning and end of the study. The results showed PBE has significant protective effects on metabolic 
syndrome factors including central obesity, TG, HDL, BP and FBS (P<0.05), decrease metabolic syndrome 
risk in obesity and improve body composition. Thus, The PBE is considered as a new approach to obesity and 
metabolic syndrome prevention. 
© 2018 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2018;56(3):196-203. 
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Introduction 
 
Metabolic syndrome refers to a clustering of 
condition related to the enhanced risk of cardiovascular 
diseases including central obesity, diabetes mellitus (or 
insulin resistance), dyslipidemia, together with 
hypertension (1). 
According to the International Diabetes Federation 
(IDF) definition, a person when considered have the 
metabolic syndrome that has Central obesity (waist 
circumference ≥94 cm for males and ≥80 cm for females 
with ethnicity specific values) plus any two of the 
following four factors: 1) Raised triglycerides (≥150 
mg/dL), 2) Reduced HDL cholesterol (<40 mg/dl in 
males and <50 mg/dl in females), 3) Raised blood 
pressure (systolic BP ≥130 or diastolic BP ≥85 mm Hg) 
and 4) Raised fasting plasma glucose (≥100 mg/dL), or 
previously diagnosed type 2 diabetes (2). 
Metabolic syndrome basically is associated with 
central obesity. Central obesity increases visceral fat 
which is combined with a higher flux of free fatty acid 
derived adipose tissue into the liver via the splanchnic 
circulation. These result in very low-density lipoprotein 
(VLDL  ( synthesis, hypertriglyceridemia, more release of 
glucose from the liver, subsequently hyperinsulinemia 
and insulin resistance (3). Additionally, evidence 
demonstrated that visceral fat has higher capacity to 
secrete proinflammatory adipokines such as interleukin-
6, tumor necrosis factor-α and C-reactive protein. These 
inflammatory cytokines have higher levels of metabolic 
syndrome patients (4). However, observations show that 
5-10% weight loss through diet therapy and exercise 
(using anti-obesity drugs or not) can reduce all 
metabolic syndrome components as well as the risk of 
cardiovascular disease and diabetes (5,6).  
Pine bark extract (PBE) with registered trade name 
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Pycnogenol® is a specific blend of phenolic compounds, 
consisting of phenolic acids, catechin, taxifolin, and 
procyanidins extracted from the bark of the pine (Pinus 
pinaster) (7). The molecular mechanisms of action of 
PBE is not known well but seems that mainly be related 
to its antioxidant properties and PBE capacity in 
scavenging free radicals, reactive oxygen and reactive 
nitrogen species (8,9). Also, it has been demonstrated 
that PBE is able to influence the expression of target 
genes modified by cell redox status (9,10). Recently the 
effects of PBE have been investigated in various in vitro 
and in vivo as well as clinical studies (11,12). 
Additionally, the PBE has shown that has suppressive 
effects on NF-κB transcription factors, a key factor-
mediated inflammatory process, and expression of genes 
involved in inflammation pathway (11). The anti-
inflammatory and cardiovascular bioefficacy of maritime 
PBE is demonstrated in numerous inflammatory 
conditions (11,13-15). Also, recent studies have indicated 
the protective features of PBE on metabolic syndrome 
components such as fasting blood sugar (FBS), high-
density lipoprotein (HDL) cholesterol, triglyceride (TG), 
and waist circumference (16). Human studies show that 
PBE is able to decrease hypertension and lower FBS and 
HbA1c significantly and improve cardiovascular and 
metabolic risk factors (17).  
However, although the growing interest in PBE 
supplementation among recent studies, the only limited 
clinical trials data are available particular in obesity and 
preventive net effects of PBE on metabolic syndrome 
risk. In this context present study aimed to evaluate the 
synergistic and net effect of French maritime PBE 
supplementation along with a weight loss diet on 
metabolic syndrome risk factors and body composition 
in obese women.  
  
Materials and Methods 
 
Patients and supplementation 
The present study was a Randomized Double-Blind 
Placebo-Control Clinical Trial (RCT). Fifty healthy 
obese women (BMI= 30-35 kg/m2) aged 18-45 years old 
were enrolled in this study. Patients were informed 
about the aim of the study. At the start of study, a 
written informed consent of Tehran University Medical 
of Sciences (TUMS) was obtained from all subjects. 
Participants were divided into two randomly allocated 
groups (PBE or placebo). Subjects could withdraw from 
the survey for any reason at any time. Exclusion criteria 
included pregnancy, lactation or menopause, use of any 
medication or presence of any other clinical condition 
and failure to follow the regime. In the present study, 5 
women in PBE group (1 for pregnancy, 1 for sensitivity 
and skin rash, 3 for unwillingness to cooperate) and 7 
women in the placebo group (1 for surgery, 2 for 
migration, 4 for unwillingness to cooperate) excluded 
from the survey. 
The PBE group received Tablets with 150 mg pine 
bark extract, manufactured by Source Naturals 
(California, USA) and the placebo group took one 
placebo tablets (contain starch powder) per day for 2 
months with meal.  
 
Diet 
All participants received diet consulting and 
educational program by a nutritionist. Everyone received 
a standard weight loss regime for two months (minus 
500 calories) and advised not to change his or her 
physical activity during the intervening period. To 
calculate total energy expenditure (TEE)، Resting 
energy expenditure (REE) was measured by indirect 
calorimetry (MetaCheck, KORR Medical Technologies, 
Inc., Salt Lake City, UT) as usual protocol (18). The 
activity thermogenesis (AT) was assessed using the 
short-form version of the International Physical Activity 
Questionnaire (IPAQ) (19). Thermic Effect of Food 
(TEF) is calculated as no more than an additional 10% 
of the REE added to the sum of the REE and AT. For 
each participant TEE was calculated by the formula 
(TEE=REE+TEF+AT) (20). The energy of weight loss 
diet calculated by reducing 500 calories from TEE. Diet 
compositions are summarized in table 1.  
 
Table 1. Composition of diets 
Carbohydrate (% of energy) 57.3 
Fat (% of energy) 16.9 
Protein (% of energy) 29.2 
SFA (% of energy) 7.2 
MUFA (% of energy) 8.1 
PUFA (% of energy) 9.1 
Fiber (gr) 22 
SFA, saturated fatty acids; MUFA, Monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids 
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Measurements of anthropometric, laboratory, and 
body composition data 
Anthropometric parameters including weight, height, 
waist circumference, and hip circumference were 
measured according to standard protocol as well as 
systolic blood pressure (SBP) and diastolic blood 
pressure (DBP). Body mass index (BMI) and waist to 
hip ratio (WHR) were calculated using weight 
(kg)/height (m2) and waist circumference (cm)/ hip 
circumference (cm) method respectively (21).  
The weight was measured with minimal clothing and 
no shoes. The height was measured in standing position, 
without shoes, paired legs, and heels in tangent situation 
with the wall. Waist circumference was measured at the 
midpoint between the lower margin of the least palpable 
rib and the top of the iliac crest, by a stretch‐resistant 
tape. Hip circumference was measured around the 
widest portion of the buttocks, with the tape parallel to 
the floor (22,23). Ten ml blood samples were taken from 
subjects. Two ml of blood was poured into CBC tubes 
(containing EDTA). The rest of blood samples were 
used to evaluate FBS, TG, HDL, T3, T4, and TSH (22).  
At the start and at the end of the study, body 
composition also was evaluated by Bioelectrical 
Impedance Analysis method (Tanita body composition 
analyzer, BC-418MA) included fat mass, fat-free mass, 
abdominal fat and total water of body. In addition, at the 
end of the study, adverse events were recorded. 
 
Statistical analysis 
For statistical analysis, SPSS 20.0 was used. Data are 
expressed as mean±SD. Kolmogorov-Smirnov 
distribution test was used for assessing normality. The 
paired t-test was used for comparisons within groups. 
For comparisons between groups ANCOVA test 
(analysis of covariance) was used. The test level for 
statistical significance of differences between both 
treatment arms was defined as P≤0.05 for all tests. 
 
Results 
 
General information 
Fifty volunteer participants based on inclusion 
criteria (female, BMI= 30-35 kg/m2) were enrolled in 
this survey. Demographic and clinical properties of 
participants in the two groups are illustrated in table 2. 
There were no statistically significant differences in age, 
weight, height, or physical activity level among the PBE 
and placebo groups (P>0.05). 
 
Table 2. Demographic information 
 Placebo (n=25) Pine bark extract (n=25) P 
Age (years) 37.3 (8.5) 37.4 (8.8) 0.97 
Height (cm) 159.5 (4.7) 159.8 (3.5) 0.86 
Weight (kg) 82.4 (6.3) 83.3 (4.3) 0.62 
Physical activity level* 1.30 (0.08) 1.31 (0.04) 0.20 
*Sedentary:1.3, low Active:1.5, Active: 1.8, Very Active: 2.0 
 
BMI and body weight 
A significant weight loss was observed in 
intervention, and placebo groups (4.58 and 3.72 kg 
respectively) and PBE group showed a more reduction 
compared to placebo group. In PBE group, BMI change 
was significant from 32.65 (1.7) kg/m2 to 30.87 (1.6) 
kg/m2 (P=<0.001) that was more than placebo group 
over 2 months follow-up. The changes in BMI and body 
weight were significant between groups at the end of 
study (P<0.05).  
 
Central obesity and fat distribution  
As shown, central obesity and fat distribution were 
assessed by the measure of waist circumference, hip 
circumstance, and WHR. In the present study, mean 
waist circumference was decreased significantly in both 
PBE and placebo groups after 2 months of 
supplementation (from 97.1 (9.4) cm to 89.8 (7.0) cm in 
PBE group and from 98.5 (8.2) cm to 92.2 (5.4) cm in 
the placebo group). Moreover, a reduction was found in 
hip circumstance in 2 groups with a decrease from 117.6 
(4.6) cm to 111.5 (4.0) cm in the intervention group and 
116.5 (5.4) cm to 109.3 (4.2) cm in control group. The 
decrease was statistically significant compared to 
baseline. WHR showed a negligible reduction in PBE 
group (from 0.827 (0.091) to 0.805 (0.059)) after 2-
month PBE supplementation that was not significant 
statistically (P=0.051) (Table 3). WC showed greater 
reduction in PEB groups versus placebo-receiving 
group.  
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Table 3. Weight, BMI, waist and circumstance, WHR, SBP, DBP, FBS, and TG 
  
Pine bark extract 
(n=20) 
Placebo group 
(n=25) 
 
P b 
Weight (kg) 
Before 83.3 (4.3) 82.5 (6.5) 0.65 
After 78.4 (4.00) 78.8 (6.5) 0.004 c 
Differences  -4.8 (1.34) -3.7 (0.4) 0.004 
P a <0.001 <0.001  
BMI (kg/m2) 
Before 32.6 (1.7) 32.38 (1.9) 0.67 
After 30.8 (1.6) 30.92 (1.9) 0.001 c 
Differences  -1.7 (0.2) -1.46 (0.1) 0.001 
P a <0.001 <0.001  
Waist circumstance (cm) 
Before 97.1 (9.4) 98.5 (8.2) 0.64 
After 89.8 (7.0) 92.2 (5.4) 0.23 c 
Differences  -7.2 (5.0) -6.2 (5.9) 0.58 
P a <0.001 0.001  
Hip circumstance (cm) 
Before 117.6 (4.6) 116.5 (5.4) 0.49 
After 111.5 (4.0) 109.3 (4.2) 0.08 c 
Differences  -6.1 (1.6) -7.1 (3.5) 0.26 
P a <0.001 <0.001  
WHR 
Before 0.82 (0.091) 0.84 (0.06) 0.48 
After .80 (0.059) 0.84 (0.05) 0.007 c 
Differences  -0.21 (0.01) 0.001 (0.007) 0.14 
P a 0.05 0.84  
SBP (mm Hg) 
Before 12.1 (1.2) 11.5 (2.2) 0.27 
After 10.0 (0.9) 10.9 (1.5) <0.001 c 
Differences  -2.1 (0.9) -0.5 (1.5) 0.001 
P a <0.001 0.18  
DBP (mm Hg) 
Before 8.1 (1.1) 8.0 (0.9) 0.82 
After 7.3 (1.0) 7.8 (0.9) 0.06 c 
Differences  -0.8 (0.8) -0.2 (0.9) 0.084 
P a <0.001 0.2  
FBS ( mg/dl) 
Before 89.3 (23.8) 89.0 (14.3) 0.96 
After 79 (10.9) 86.6 (7.5) 0.005 c 
Differences  -9.6 (15.2) -2.3 (14.8) 0.16 
P value a 0.01 0.5  
TG ( mg/dl) 
Before 111.5 (41.8) 118.6 (45.3) 0.62 
After 110.5 (33.1) 132.0 (42.8) 0.03 c 
Differences  -1.0 (23.8) 13.37 (28.28) 0.10 
P a 0.85 0.07  
HDL ( mg/dl) 
Before 41.9 (9.2) 41.9 (7.0) 0.98 
After 45.7 (8.5) 40.0 (7.4) 0.01 c 
Differences  3.8 (8.0) -1.9 (5.2) 0.01 
P a 0.04 0.15  
Metabolic syndrome risk 
factors 
Before 2.85(1.2) 2.8 (1.3) 0.95 
After 2.15(0.8) 2.5 (1.1) 0.14 c 
Differences  -0.7 (0.9) -0.3 (1.0) 0.25 
P a 0.005 0.2  
a paired samples t-test  
b one way ANOVA 
c ANCOVA test  
BMI, Body Mass Index; WHR, Waist to Hip ratio; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; FBS, Fasting Blood Sugar; 
TG,  Triglyceride; HDL, High-Density Lipoprotein;  
 
 
Lipid profile (TG and HDL cholesterol) 
 No significant differences were observed in the 
mean level of TG in PBE or control group when 
compared to baseline and after 2-month supplementation 
(P>0.05) but a very more reduction was seen in PBE 
group. However, TG changes between 2 groups were 
significant (P<0.05). HDL cholesterol levels were also 
significantly improved in the PBE group compared to 
baseline as increase from 41.9 (9.2) mg/dl at baseline to 
45.7 (8.5) mg/dl at the end of study (P<0.05). In control 
group, the changes of HDL was not statistically 
significant (P>0.05).  
PBE and improve body composition 
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Blood pressure 
Systolic and diastolic blood pressures were 
monitored at the baseline and after 2 months of 
supplementation. The mean SBP decreased significantly 
(P<0.05) in the treatment group and placebo group. A 
similar significant reduction for DBP mean also was 
observed only in PBE group compared to baseline 
(P<0.05).  
 
Fasting blood sugar 
The FBS values improved significantly in the PBE 
group from 89.3 (23.8) mg/dl to 79 (10.9) after 2 months 
of receiving PBE (P<0.05). A slight decrease of FBS 
was found in the placebo group compared to baseline, 
but it was not statistically significant (P>0.05). Also, 
these changes were significant between groups. 
 
Body composition results 
As we can see in table 4, fat mass, free fat mass, 
abdominal fat and total body water show significant 
changes in treatment and placebo groups (P<0.05) with 
more improvement in PBE group. 
 
Table 4. Body composition 
  
Pine bark extract 
(n=20) 
Placebo group (n=25) P b 
FM (kg) 
Before 34.0 (2.6) 32.9 (4.5) 0.34 
After 31.0 (2.3) 30.7 (4.7) 0.03 c 
P a <0.001 <0.001  
FFM (kg) 
Before 48.5 (3.2) 48.9 (2.2) 0.65 
After 47.7(3.1) 47.7 (2.7) 0.2 c 
P a 0.009 <0.001  
Abdominal Fat (kg) 
Before 38.3 (3.7) 36.2 (2.7) 0.1 
After 36.3 (3.8) 35.1 (3.0) 0.4 c 
P a <0.001 0.001  
Total water (% of 
body weight) 
Before 43.0 (2.0) 44.2 (2.2) 0.1 
After 44.2 (2.4) 44.9 (2.3) 0.04 c 
P a <0.001 0.001  
* paired samples t-test  
** ANCOVA test  
FFM: Free Fat Mass, FM: Fat Mass, REE: Resting Energy Expenditure 
 
Metabolic syndrome risk 
As data shown in table 3, the metabolic syndrome 
risk decreased only in supplementation group (from 2.85 
(1.22) to 2.15(0.87)) which was statistically significant 
(P<0.05). Prevalence of the metabolic syndrome risk 
factors in the study subjects at inclusion 5/5 risk factors 
of the metabolic syndrome was present in all subjects as 
per inclusion criteria (Table 5). 
 
Table 5. Prevalence of the metabolic syndrome risk factors 
 
Risk 
factors 
present 
Inclusion 
Baseline At 2 months 
Placebo 
Pine bark 
extract 
Placebo 
pine bark 
extract 
Number 
(%) 
Number 
(%) 
Number 
(%) 
Number 
(%) 
Metabolic Syndrome zone 
5/5 100% 3 (12) 3 (12) 1 (5.6) 0 (0) 
4/5 0 4 (16) 6 (24) 2 (11.1) 2 (10) 
3/5 0 6 (24) 4 (16) 5 (27.8) 3 (15) 
Borderline Out of metabolic 
syndrome 
2/5 0 9 (36) 9 (36) 9 (50) 11 (55) 
1/5 0 3 (12) 3 (12) 0 (0) 4 (20) 
0/5 0 0 (0) 0 (0) 1 (5.6) 0 (0) 
 
 
Safety 
During this study, all subjects except one did not 
disclose any side effects. One of the participants in the 
PBE group reported red skin rash while taking the PBE. 
No significant changes were observed in vital signs or 
blood parameters measured at baseline and after 2 
months of treatment including CBC and Thyroid gland 
function (P>0.05) (Table 2). 
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Discussion 
 
Metabolic syndrome is a cluster of risk factors which 
increase the risk of cardiovascular diseases as well type 
2 diabetes and stroke. Evidence well demonstrated that 
metabolic syndrome is associated with a 
proinflammatory condition (24). Obesity particularly 
central obesity is characterized by chronic low-grade 
inflammation and play a key role in the pathogenesis of 
metabolic syndrome (25). In addition, oxidative stress 
which is considered as a mechanism behind the risk of 
this syndrome, diabetes, and cardiovascular disease is 
associated with obesity (26).  
The previous study demonstrated the beneficial 
effects of PBE in patients with metabolic syndrome or 
cardiovascular disease, but there is not a study regarding 
the combination of PBE with weight reduction in order 
to determine the net effects of PBE on metabolic risk 
factors and body composition in obese subjects. The 
current study is the first one that examines this effects 
(16,17).  
In the present study, it was shown that 2 months of 
PBE administration in obese women who received 
weight loss regime significantly reduces weight, BMI, 
hip circumstance, WHR and exerts significant protective 
effects against metabolic syndrome factors including 
central obesity, TG, HDL, blood pressure, FBS, and 
significantly decreases metabolic syndrome risk in obese 
population. Moreover, it improves body composition.  
The PBE a specific blend of procyanidins extracted 
from the bark of the pine has been demonstrated to 
contribute to antioxidant network and exerts radical-
scavenging activity (9). In addition, Pycnogenol inhibits 
inflammatory response through suppressing of NF-κB-
dependent gene expression (11). Also, Gallic Acid as an 
antioxidant component in PBE regulates body weight 
and glucose homeostasis without a change in food intake 
through activation of 5' AMP-activated protein kinase 
(AMPK) and proliferator-activated receptor-γ 
coactivator1α (PGC1α) in animal (27). Therefore, PBE 
can be beneficial in the context of glucose hemostasis 
and inflammation induced obesity, the conditions 
contributing to the pathogenesis of metabolic syndrome.  
The results of present study show a greater reduction 
in BMI, weight, and WC in subjects who received PBE 
supplementation. Experimental evidence confirm these 
results and indicate that Pycnogenol enhances fat 
oxidation and lipolysis (28,29) and has preventive 
effects against metabolic syndrome (30). However, 
Belcaro et al., reported that administration of 
Pycnogenol for 6 months in patients with metabolic 
syndrome has limited effects on weight and BMI 
reduction (16). They also showed that Pycnogenol 
significantly reduces TG levels, blood pressure and 
increases HDL and significantly improves FBS which is 
parallel with our study. In another study, mean of 
HbA1c decreased by 0.8% in pycnogenol 
supplementation as well as fasting plasma glucose 
versus the control group (31). Moreover, experimental 
studies confirm these results and pine bark extract can 
significantly reduce levels of glycosylated hemoglobin 
and increase hepatic glycogen level (32). The known 
mechanisms of lowering FBS is that PBE inhibits α-
glucosidase activity resulted in decrease of glucose 
absorption and postprandial hyperglycemia (27,33,34). 
Also, PBE significantly ameliorated oxidative stress 
such as thiobarbituric reactive substances, 
malonaldehyde, protein carbonyl, and glutathione and 
increase antioxidant enzymes including catalase, 
superoxide dismutase, glutathione S transferase, 
glutathione peroxidase, and glutathione reductase (32).  
In the present study, 2 months of PBE 
supplementation showed a significant reduction in 
systolic and diastolic blood pressure but not in the 
placebo group. Based on previous observation, pine bark 
extract treatment showed 58.3% decrease in blood 
pressure of diabetic patients and 50% reduction in 
individual who take anti-blood pressure drugs. PBE is 
able to reduce endothelin-1 which contributes to 
endothelium contraction and hypertension (31). In this 
context, observation suggested that PBE acts as a 
vasodilator agent and can significantly improve 
endothelial function, venous tone, blood flow perfusion 
and decreases blood pressure and hypertension (35-38).  
Additionally, in our study, PBE increased HDL 
significantly. There are evidence that PBE positively 
influences lipid profile in populations. Devaraj et al. 
observed a significantly improved blood lipid profile 
(decreased LDL) in young healthy subjects. Also, 
supplementation with PBE for 6 weeks significantly 
increased HDL which is similar to our results (39). 
Parallel with our results, Devaraj et al., showed that 
supplementation with a pine bark extract rich in 
polyphenols significantly reduces LDL-cholesterol and 
increases HDL-cholesterol levels in the blood as well as 
antioxidant activity (39). So, PBE exerts cardiovascular 
protective properties and can be considered as an 
effective compound in metabolic disorders.  
Altogether, the results of this study suggested that 
PBE, an antioxidant and anti-inflammatory compound 
might play a role as adjuvant therapy and in combination 
with weight loss/ lifestyle modification can reduce the 
PBE and improve body composition 
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risk of metabolic syndrome factors and improve body 
composition in order to fat mass reduction. 
In conclusion, the current study suggests a role for 
PBE that along with weight loss can improve the cluster 
of features associated with metabolic syndrome 
(dyslipidemia, hyperglycemia, hypertension and 
elevated TG). The PBE acts through multiple 
mechanisms such as contributing to antioxidant network 
and suppression of inflammatory-mediated factors and 
gene expression levels. It seems that PBE as a natural 
and side effects free alternative compound can be 
noticed in high-risk subjects with changes in lifestyle. 
However, the clinical data for pharmaceutical usage are 
limited and clearly, for understanding of the molecular 
action of PBE further studies are needed.  
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